Contact
searchSearch
HMP Global

Gastroenterology

Featured

Research Highlights
MAPI Offers New Biomarker in Screening for MetALD and ALD
04/23/2026
Jessica Garlewicz
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index...
04/23/2026
Gastroenterology
Expert Roundtable
Advances in the Pipeline for MASLD/MASH
04/17/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
In the final installment of the expert roundtable on MASLD/MASH, Drs Afdhal, Bansal, and Younossi discuss the most promising new candidate drugs in development for treatment, including some that may reverse fibrosis.
In the final installment of the expert roundtable on MASLD/MASH, Drs Afdhal, Bansal, and Younossi discuss the most promising new candidate drugs in development for treatment, including some that may reverse fibrosis.
In the final installment of the...
04/17/2026
Gastroenterology
Expert Roundtable
Monitoring Patients With MASLD/MASH
04/17/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
Our expert roundtable on MASLD/MASH reviews how to monitor patients on treatment for MASLD/MASH, including the use of PEth tests to detect alcohol consumption that may be reducing efficacy of medical therapies.
Our expert roundtable on MASLD/MASH reviews how to monitor patients on treatment for MASLD/MASH, including the use of PEth tests to detect alcohol consumption that may be reducing efficacy of medical therapies.
Our expert roundtable on...
04/17/2026
Gastroenterology
Expert Roundtable
GLP-1s, Resmetirom, Dual Therapy and More: Roundtable Continued
03/30/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
Continuing their discussion on treatment for MASLD/MASH, the expert roundtable members delve into treatment of early-stage cirrhosis and the utility of bariatric surgery for a subset of patients with these liver diseases.
Continuing their discussion on treatment for MASLD/MASH, the expert roundtable members delve into treatment of early-stage cirrhosis and the utility of bariatric surgery for a subset of patients with these liver diseases.
Continuing their discussion on...
03/30/2026
Gastroenterology
Expert Roundtable
Approved Medications for MASLD/MASH
03/30/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
In Part 5 of this roundtable discussion, Drs Afdhal, Bansal, and Younossi review the approved medications resmetirom and GLP-1 receptor agonists for MASLD/MASH, including how they work, selecting patients best suited for each, using dual...
In Part 5 of this roundtable discussion, Drs Afdhal, Bansal, and Younossi review the approved medications resmetirom and GLP-1 receptor agonists for MASLD/MASH, including how they work, selecting patients best suited for each, using dual...
In Part 5 of this roundtable...
03/30/2026
Gastroenterology
FDA Alert
FDA Approves Linerixibat for Pruritis in PBC
03/20/2026
Rebecca Mashaw
The US Food and Drug Administration (FDA) on March 19 approved linerixibat for the treatment of cholestatic pruritus in adult patients with PBC. The ileal bile acid transporter (IBAT) inhibitor reduces multiple drivers of chronic itch, which...
The US Food and Drug Administration (FDA) on March 19 approved linerixibat for the treatment of cholestatic pruritus in adult patients with PBC. The ileal bile acid transporter (IBAT) inhibitor reduces multiple drivers of chronic itch, which...
The US Food and Drug...
03/20/2026
Gastroenterology
Research Highlights
Dynamic FIB-4 Changes Track Fibrosis Progression and Predict Outcomes in MASLD
03/18/2026
Jessica Garlewicz
Findings of a recent analysis suggest that serial FIB-4 monitoring may provide prognostic value beyond a single baseline measurement.
Findings of a recent analysis suggest that serial FIB-4 monitoring may provide prognostic value beyond a single baseline measurement.
Findings of a recent analysis...
03/18/2026
Gastroenterology
Research Highlights
Colonic Microbiota Dysbiosis Tied to IBS-C Pathophysiology
03/18/2026
Rebecca Mashaw
Colonic microbiota dysbiosis appears central to IBS-C pathophysiology, affecting motility, inflammation, and gut-brain interactions.
Colonic microbiota dysbiosis appears central to IBS-C pathophysiology, affecting motility, inflammation, and gut-brain interactions.
Colonic microbiota dysbiosis...
03/18/2026
Gastroenterology
Gut Check logo
Expert Insights
Gut Check: Darren Brenner, MD, on Bloating and Distention
03/16/2026
Brian E. Lacy, PhD, MD; Darren Brenner, MD
In this episode of Gut Check, host Brian Lacy, MD, and guest Dr Darren Brenner discuss the common symptoms of gas, distension, and bloating--what distinguishes each from the others, possible causes, and how to treat these prevalent...
In this episode of Gut Check, host Brian Lacy, MD, and guest Dr Darren Brenner discuss the common symptoms of gas, distension, and bloating--what distinguishes each from the others, possible causes, and how to treat these prevalent...
In this episode of Gut Check,...
03/16/2026
Gastroenterology
Expert Insights
The "Dream Team" for Managing IBS-C Needs GI Psychologist and Dietician
03/11/2026
Megan Riehl, PsyD; Kate Scarlata, RDN
GI psychologist Megan Riehl and registered dietician and nutritionist Kate Scarlata discuss how their specialty care can help patients with constipation-predominant irritable bowel syndrome and which patients are the best candidates for...
GI psychologist Megan Riehl and registered dietician and nutritionist Kate Scarlata discuss how their specialty care can help patients with constipation-predominant irritable bowel syndrome and which patients are the best candidates for...
GI psychologist Megan Riehl and...
03/11/2026
Gastroenterology
Identification of Fibrosis
Machine Learning Tool Improves Noninvasive Identification of F2 Fibrosis in MASH
02/17/2026
Jessica Garlewicz
A new machine learning–based calculator may improve identification of patients with metabolic dysfunction–associated steatohepatitis (MASH) who meet fibrosis thresholds for resmetirom therapy, according to results from the ALADDIN study.
A new machine learning–based calculator may improve identification of patients with metabolic dysfunction–associated steatohepatitis (MASH) who meet fibrosis thresholds for resmetirom therapy, according to results from the ALADDIN study.
A new machine learning–based...
02/17/2026
Gastroenterology

News

Research Highlights
MAPI Offers New Biomarker in Screening for MetALD and ALD
04/23/2026
Jessica Garlewicz
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index...
04/23/2026
Gastroenterology
News
Lifetime Alcohol Intake Linked to Colorectal Cancer Risk
02/11/2026
Jessica Garlewicz
For gastroenterologists, the key takeaway is that cumulative alcohol exposure and long-term drinking patterns matter when assessing CRC risk.
For gastroenterologists, the key takeaway is that cumulative alcohol exposure and long-term drinking patterns matter when assessing CRC risk.
For gastroenterologists, the key...
02/11/2026
Gastroenterology
Research Review
New Meta-Analysis Highlights Burden of MASLD Among IBD Patients
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
Emerging Therapies
EC Plus FOLFIRI Improves Response Rates in First-Line BRAF V600E–Mutant Metastatic Colorectal Cancer
01/14/2026
Jessica Garlewicz
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating...
01/14/2026
Gastroenterology
Research Highlights
Short Course Radiation and ctDNA for Rectal Cancer
01/14/2026
Jessica Garlewicz
In an abstract presented at the ASTRO meeting, investigators indicated that circulating tumor DNA may predict recurrence of rectal cancer following short-course radiation therapy.
In an abstract presented at the ASTRO meeting, investigators indicated that circulating tumor DNA may predict recurrence of rectal cancer following short-course radiation therapy.
In an abstract presented at the...
01/14/2026
Gastroenterology
Research Highlights
Persistent MASLD Greatly Increases Diabetes and Cardiovascular Risks, Study Finds
12/15/2025
Rebecca Mashaw
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links...
12/15/2025
Gastroenterology
Research Highlights
Sex-Specific Risks Highlight MASLD Burden Across Women’s Lifespan
12/11/2025
Rebecca Mashaw
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD...
12/11/2025
Gastroenterology
Conference Coverage
Resmetirom Reduces Portal Hypertension Risk and Fibrosis Markers in MASH Cirrhosis at 2 Years
11/04/2025
Jessica Garlewicz
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients...
11/04/2025
Gastroenterology
Conference Coverage
Tirzepatide Bests Semaglutide in Reducing Cardiovascular Events and Mortality in Patients With MASLD/MASH
11/04/2025
Jessica Garlewicz
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was...
11/04/2025
Gastroenterology
Conference Coverage
E-Cigarette Use and Risk of Peptic Ulcer Disease: Findings from a National Cohort
10/27/2025
Rebecca Mashaw
In an oral abstract presented at the ACG meeting, investigators concluded that e-cigarette use—both current and former—is independently associated with a risk of peptic ulcer disease.
In an oral abstract presented at the ACG meeting, investigators concluded that e-cigarette use—both current and former—is independently associated with a risk of peptic ulcer disease.
In an oral abstract presented at...
10/27/2025
Gastroenterology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use